2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isa-Pom-Dex in Elderly/Frail Subjects With RRMM Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Relapse | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 6 | 2023-12-05 | 2026-06-09 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Daratumumab, Carfilzomib, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Andrew Yee, MD | 44 | 2020-05-18 | 2026-10-15 |
Multiple Myeloma (2) · Recurrence (2)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Pathologic Processes (2)
Dexamethasone (2) · pomalidomide (2) · carfilzomib (1) · daratumumab (1) · isatuximab (1)
Andrew Yee, MD (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (2)
Andrew J Yee, MD (1) · Eben I Lichtman, MD (1)